Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II gene therapy study of AAV.GTX-ADAR2 for sporadic ALS
jRCT2033210686Phase 2Active, not recruiting
- Sponsor
- ONODERA GT Pharma
- Start
- Mar 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAV.GTX-ADAR2 in amyotrophic lateral sclerosis (ALS), sponsored by ONODERA GT Pharma. Started Mar 2023; status: active, not recruiting.
02
Drugs
AAV.GTX-ADAR2
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2033210686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210686.